Source 1primary paper2026MED
Toolkit/lipid nanoparticle
lipid nanoparticle
Also known as: lipid nanoparticle (LNP), LNP
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
increasing clinical experience with in-vivo editing - particularly using lipid nanoparticle (LNP) and adeno-associated virus (AAV)-based platforms - that has also revealed important safety considerations
Usefulness & Problems
Why this is useful
Lipid nanoparticles are presented as a delivery platform relevant to mRNA vaccines for tuberculosis prevention. In this review context, they are part of the platform-design problem rather than a disease antigen themselves.; mRNA vaccine delivery; LNPs are described as in vivo editing delivery platforms with growing clinical experience.; in vivo delivery for gene editing; clinical in vivo editing platforms; LNPs are presented as a non-viral delivery system in gene therapy. The abstract states that they have led to successful gene therapy products.; non-viral gene delivery; platforms associated with successful gene therapy products
Source:
Lipid nanoparticles are presented as a delivery platform relevant to mRNA vaccines for tuberculosis prevention. In this review context, they are part of the platform-design problem rather than a disease antigen themselves.
Source:
mRNA vaccine delivery
Source:
LNPs are described as in vivo editing delivery platforms with growing clinical experience.
Source:
in vivo delivery for gene editing
Source:
clinical in vivo editing platforms
Source:
LNPs are presented as a non-viral delivery system in gene therapy. The abstract states that they have led to successful gene therapy products.
Source:
non-viral gene delivery
Source:
platforms associated with successful gene therapy products
Problem solved
It addresses the need to deliver mRNA vaccine payloads. The review scaffold frames delivery as a major platform challenge in TB mRNA vaccine development.; providing a delivery platform for mRNA vaccine payloads; They help address the need to deliver editing systems in vivo.; enabling in vivo delivery of editing systems; They provide a non-viral alternative for therapeutic nucleic acid delivery.; provides a non-viral delivery modality for gene therapy
Source:
It addresses the need to deliver mRNA vaccine payloads. The review scaffold frames delivery as a major platform challenge in TB mRNA vaccine development.
Source:
providing a delivery platform for mRNA vaccine payloads
Source:
They help address the need to deliver editing systems in vivo.
Source:
enabling in vivo delivery of editing systems
Source:
They provide a non-viral alternative for therapeutic nucleic acid delivery.
Source:
provides a non-viral delivery modality for gene therapy
Problem links
enabling in vivo delivery of editing systems
LiteratureThey help address the need to deliver editing systems in vivo.
Source:
They help address the need to deliver editing systems in vivo.
provides a non-viral delivery modality for gene therapy
LiteratureThey provide a non-viral alternative for therapeutic nucleic acid delivery.
Source:
They provide a non-viral alternative for therapeutic nucleic acid delivery.
providing a delivery platform for mRNA vaccine payloads
LiteratureIt addresses the need to deliver mRNA vaccine payloads. The review scaffold frames delivery as a major platform challenge in TB mRNA vaccine development.
Source:
It addresses the need to deliver mRNA vaccine payloads. The review scaffold frames delivery as a major platform challenge in TB mRNA vaccine development.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A delivery strategy grouped with the mechanism branch because it determines how a system is instantiated and deployed in context.
Techniques
Computational DesignTarget processes
editingrecombinationtranslationImplementation Constraints
cofactor dependency: requires exogenous cofactorencoding mode: externally suppliedimplementation constraint: context specific validationimplementation constraint: payload burdenoperating role: delivery
Use requires mRNA formulation into an LNP delivery system. The supplied evidence does not specify composition or manufacturing details for this review.; requires formulation design appropriate for mRNA vaccine delivery; They function as delivery vectors for in vivo editing and therefore require compatible gene-editing cargo and systemic administration context.; requires management of safety considerations in vivo; must support efficient and precise delivery for clinical translation
The supplied evidence does not show that LNPs alone solve antigen selection, immunogenicity optimization, or safety tradeoffs. Delivery challenges remain explicitly noted.; the supplied evidence only generally indicates delivery challenges; The abstract indicates that LNP use does not eliminate safety concerns such as immunogenicity, systemic inflammation, and organ-specific toxicity.; associated with vector immunogenicity; associated with systemic inflammation; associated with organ-specific toxicities
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Source 2review2026PMC
Source 3primary paper2025MED
Ranked Claims
The supplied evidence frames the mRNA tuberculosis vaccine evidence base as still sparse despite emerging preclinical and early clinical activity.
The review covers preclinical mRNA tuberculosis vaccine efficacy and mechanisms, platform and delivery challenges including LNP and saRNA design, and early human clinical translation represented by BNT164.
Increasing clinical experience with in vivo editing using LNP- and AAV-based platforms has revealed safety considerations including vector immunogenicity, systemic inflammation, and organ-specific toxicities.
Next-generation editors and targeted delivery systems have expanded the scope of feasible cardiovascular applications, but biological barriers still limit translation to well tolerated durable one-time genomic therapies.
Emerging editing technologies aim to overcome limited vector cargo capacity, PAM incompatibility, chromatin accessibility, suboptimal editing efficiency, and off-target activity.
Successful clinical translation of gene and base editing for cardiovascular disease depends on efficient and precise delivery and on mitigating immunogenicity and toxicity from both delivery vectors and gene-editing enzymes.
AAV-based gene therapy has achieved approved clinical use, including Luxturna for a genetic retinal disease.
including the approval of Luxturna for a genetic retinal disease
First-in-human dual AAV therapy for hereditary hearing loss showcased restoration of auditory function in patients.
has showcased the restoration of auditory function for patients
LNP and GalNAc non-viral vectors have led to successful gene therapy products.
non-viral vectors such as lipid nanoparticles (LNP) and N-acetylgalactosamine (GalNAc) have led to successful gene therapy products
Dual AAV therapy can overcome large gene delivery limitations.
the first-in-human dual AAV therapy for hereditary hearing loss, which overcomes large gene delivery
Lentiviral vectors, adenoviral vectors, and AAV are widely used viral vectors that have enabled notable preclinical and clinical successes in gene therapy over the past two decades.
Over the past two decades, three widely used viral vectors-lentiviruses (LV), adenoviruses (Ad), and adeno-associated viruses (AAV)-have enabled notable preclinical and clinical successes
Approval Evidence
3 sources5 linked approval claimsfirst-pass slug lipid-nanoparticle
increasing clinical experience with in-vivo editing - particularly using lipid nanoparticle (LNP) and adeno-associated virus (AAV)-based platforms - that has also revealed important safety considerations
Source:
The supplied review scaffold explicitly highlights platform/delivery challenges including LNP and saRNA design in the context of mRNA tuberculosis vaccines.
Source:
Additionally, non-viral vectors such as lipid nanoparticles (LNP) and N-acetylgalactosamine (GalNAc) have led to successful gene therapy products.
Source:
review scope summarysupports
The review covers preclinical mRNA tuberculosis vaccine efficacy and mechanisms, platform and delivery challenges including LNP and saRNA design, and early human clinical translation represented by BNT164.
Source:
safety risksupports
Increasing clinical experience with in vivo editing using LNP- and AAV-based platforms has revealed safety considerations including vector immunogenicity, systemic inflammation, and organ-specific toxicities.
Source:
scope expansionsupports
Next-generation editors and targeted delivery systems have expanded the scope of feasible cardiovascular applications, but biological barriers still limit translation to well tolerated durable one-time genomic therapies.
Source:
translation constraintsupports
Successful clinical translation of gene and base editing for cardiovascular disease depends on efficient and precise delivery and on mitigating immunogenicity and toxicity from both delivery vectors and gene-editing enzymes.
Source:
clinical translationsupports
LNP and GalNAc non-viral vectors have led to successful gene therapy products.
non-viral vectors such as lipid nanoparticles (LNP) and N-acetylgalactosamine (GalNAc) have led to successful gene therapy products
Source:
Comparisons
Source-stated alternatives
The same scaffold also mentions saRNA design as an adjacent platform direction. No more specific delivery alternative is directly described in the anchor review payload.; The abstract directly contrasts LNP-based platforms with AAV-based platforms.; The abstract contrasts LNPs with viral vectors and with GalNAc as another non-viral modality.
Source:
The same scaffold also mentions saRNA design as an adjacent platform direction. No more specific delivery alternative is directly described in the anchor review payload.
Source:
The abstract directly contrasts LNP-based platforms with AAV-based platforms.
Source:
The abstract contrasts LNPs with viral vectors and with GalNAc as another non-viral modality.
Source-backed strengths
treated as a central delivery platform in the review's stated scope; highlighted as a platform with increasing clinical experience; linked to successful gene therapy products
Source:
treated as a central delivery platform in the review's stated scope
Source:
highlighted as a platform with increasing clinical experience
Source:
linked to successful gene therapy products
Compared with Adeno-associated virus
The abstract contrasts LNPs with viral vectors and with GalNAc as another non-viral modality.
Shared frame: source-stated alternative in extracted literature
Strengths here: treated as a central delivery platform in the review's stated scope; highlighted as a platform with increasing clinical experience; linked to successful gene therapy products.
Relative tradeoffs: the supplied evidence only generally indicates delivery challenges; associated with vector immunogenicity; associated with systemic inflammation.
Source:
The abstract contrasts LNPs with viral vectors and with GalNAc as another non-viral modality.
Compared with lipid nanoparticles
The abstract contrasts LNPs with viral vectors and with GalNAc as another non-viral modality.
Shared frame: source-stated alternative in extracted literature
Strengths here: treated as a central delivery platform in the review's stated scope; highlighted as a platform with increasing clinical experience; linked to successful gene therapy products.
Relative tradeoffs: the supplied evidence only generally indicates delivery challenges; associated with vector immunogenicity; associated with systemic inflammation.
Source:
The abstract contrasts LNPs with viral vectors and with GalNAc as another non-viral modality.
Compared with mRNA-lipid nanoparticles
The abstract contrasts LNPs with viral vectors and with GalNAc as another non-viral modality.
Shared frame: source-stated alternative in extracted literature
Strengths here: treated as a central delivery platform in the review's stated scope; highlighted as a platform with increasing clinical experience; linked to successful gene therapy products.
Relative tradeoffs: the supplied evidence only generally indicates delivery challenges; associated with vector immunogenicity; associated with systemic inflammation.
Source:
The abstract contrasts LNPs with viral vectors and with GalNAc as another non-viral modality.
Compared with mRNA-loaded lipid nanoparticles
The abstract contrasts LNPs with viral vectors and with GalNAc as another non-viral modality.
Shared frame: source-stated alternative in extracted literature
Strengths here: treated as a central delivery platform in the review's stated scope; highlighted as a platform with increasing clinical experience; linked to successful gene therapy products.
Relative tradeoffs: the supplied evidence only generally indicates delivery challenges; associated with vector immunogenicity; associated with systemic inflammation.
Source:
The abstract contrasts LNPs with viral vectors and with GalNAc as another non-viral modality.
Compared with self-amplifying mRNA
The same scaffold also mentions saRNA design as an adjacent platform direction. No more specific delivery alternative is directly described in the anchor review payload.
Shared frame: source-stated alternative in extracted literature
Strengths here: treated as a central delivery platform in the review's stated scope; highlighted as a platform with increasing clinical experience; linked to successful gene therapy products.
Relative tradeoffs: the supplied evidence only generally indicates delivery challenges; associated with vector immunogenicity; associated with systemic inflammation.
Source:
The same scaffold also mentions saRNA design as an adjacent platform direction. No more specific delivery alternative is directly described in the anchor review payload.
Ranked Citations
- 1.
- 2.
- 3.